Entellus Medical Inc. (ENTL)

24.00
0.01 0.04
NASDAQ : Health Technology
Prev Close 24.01
Open 24.00
Day Low/High 24.00 / 24.08
52 Wk Low/High 11.47 / 25.58
Volume 43.90K
Avg Volume 351.20K
Exchange NASDAQ
Shares Outstanding 25.65M
Market Cap 615.81M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Entellus Medical Announces Third Quarter 2015 Financial Results

Entellus Medical Announces Third Quarter 2015 Financial Results

Increases Full Year Revenue Guidance

Entellus Medical is Now Oversold (ENTL)

Entellus Medical is Now Oversold (ENTL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Entellus Medical To Report Third Quarter 2015 Financial Results On November 5, 2015

Entellus Medical To Report Third Quarter 2015 Financial Results On November 5, 2015

Conference Call Scheduled for Thursday, November 5, 2015 at 4:30pm ET

Entellus Medical is Now Oversold (ENTL)

Entellus Medical is Now Oversold (ENTL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Entellus Medical Announces Release Of MiniFESS(TM) Surgical Instruments And FocESS(TM) Sinuscopes

Entellus Medical Announces Release Of MiniFESS(TM) Surgical Instruments And FocESS(TM) Sinuscopes

New Products to Facilitate the Treatment of Increasing Number of Chronic Sinusitis Patients in ENT Physician Offices

Entellus Medical Surpasses 100,000 Patients Treated Worldwide

Entellus Medical Surpasses 100,000 Patients Treated Worldwide

XprESS(TM) Balloon Sinus Dilation Systems the Most Widely Used in ENT Offices

Entellus Medical Announces Exclusive Collaboration With Fiagon

Entellus Medical Announces Exclusive Collaboration With Fiagon

Fiagon Image Guidance Technology Complements Entellus Medical's Portfolio of Products for the Treatment of Chronic Sinusitis in ENT Offices and Ambulatory Surgery Centers

Entellus Medical To Report Second Quarter 2015 Financial Results On August 6, 2015

Entellus Medical To Report Second Quarter 2015 Financial Results On August 6, 2015

Conference Call Scheduled for Thursday, August 6, 2015 at 4:30pm ET

Entellus Medical Becomes Oversold (ENTL)

Entellus Medical Becomes Oversold (ENTL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Entellus Medical Announces European Launch Of XprESS(TM) LoProfile Multi-Sinus Dilation System

Entellus Medical Announces European Launch Of XprESS(TM) LoProfile Multi-Sinus Dilation System

Company to Showcase XprESS LoProfile at the Congress of European ORL-HNS

Entellus Medical Announces First Quarter 2015 Financial Results

Entellus Medical Announces First Quarter 2015 Financial Results

Updates 2015 Financial Outlook

Entellus Medical To Report First Quarter 2015 Financial Results On May 7, 2015

Entellus Medical To Report First Quarter 2015 Financial Results On May 7, 2015

Conference Call Scheduled for Thursday, May 7, 2015 at 4:30pm ET

Entellus Medical To Report Fourth Quarter And Full Year 2014 Financial Results On March 17, 2015

Entellus Medical To Report Fourth Quarter And Full Year 2014 Financial Results On March 17, 2015

Conference Call Scheduled for Tuesday, March 17, 2015 at 4:30pm ET

Entellus Medical (ENTL) Stock Up Today on Trading Debut After Pricing IPO at $17

Entellus Medical (ENTL) Stock Up Today on Trading Debut After Pricing IPO at $17

Shares of Entellus Medical (ENTL) are rising as the medical technology company begins trading on the NASDAQ Global Market after pricing its IPO at $17 per share.